复星医药子公司帕金森病药物获批进行临床试验

本文如何被排名

Signal score

0 / 100

Composite score across the factors below. Higher = stronger signal that this story matters right now.

Newsworthiness bucket

Tool

此条目报告子公司获得药物临床试验批准，属于产品开发范畴，但并非来自主要AI实验室的前沿发布。

Source corroboration

Single-source cluster

Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.

Topics

product, policy

Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.

AI-industry relevance

Low

Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.

Story freshness

50 days old

Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。